Pharmacological enrollment of aldehyde dehydrogenase modulators to assist treating ischemia reperfusion-induced intestinal injury: is there a gap to be bridged?

Abstract

This commentary highlights the research presented by Zhu et al. [1]. In this issue of the Clinical Science, the authors evaluated the protective effect of Alda-1 (a novel class of small molecule aldehyde dehydrogenase (ALDH2) activators) in the intestinal ischemia reperfusion (IR) injury. Remarkably, enhancing the ADLH2 activity by the use of Alda-1 can ameliorate several deleterious effects related to aldehydes, and may provide a better protection against an injury preestablished by IR. Together, an innovative metabolic strategy for treating patients with IR injury could be the use of ALDH modulators in a near future.

• Authors: Laurent Dollé
• Journal: Clinical science (London, England : 1979) (Clin Sci (Lond)) Vol. 131 Issue 11 Pg. 1137-1140 (06 01 2017) ISSN: 1470-8736 [Electronic] England
• PMID: 28533269 (Publication Type: Journal Article, Comment)
• Copyright: © 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Chemical References

• Benzamides
• Benzodioxoles
• Aldehyde Dehydrogenase
• Aldehyde Dehydrogenase, Mitochondrial

Topics

• Aldehyde Dehydrogenase
• Aldehyde Dehydrogenase, Mitochondrial
• Benzamides
• Benzodioxoles
• Humans
• Reperfusion Injury